# Practical Guidance on the Application of Allergen Quantitative Risk Assessment

**Neil Buck** 









#### **Contents**

- Summary
- Project Conduct
- Project Output
- Next Steps





#### Summary

#### Yesterday

- ➤ Binary Approach
- judgement on whether allergen is potentially present or not
- lack of industry alignment
- ➤ Inaccurate information passed along supply chains
- Proliferation of Inaccurate Precautionary Labelling

#### **Today**

- Growing expectation of more accurate crosscontact understanding
- Application of allergen reference doses, and QRA

#### But ...


Lack of harmonization in when allergen QRA is appropriate and how to perform

#### **Tomorrow**

Consensus guidance on the application of allergen QRA











Stakeholder

Stakeholder

Stakeholder event

Testing period & review

Dev Food Control 138 (2022) 108917 the

Contents lists available at ScienceDirect

Food Control

journal homepage: www.elsevier.com/locate/foodcont

r feedback before nalisation Sep 2021

Allow stakeholders to apply for 6 weeks guidance before publishing

Oct/Nov 2021



CONTROL

CONTROL

CONTROL CONTROL

CONTROL

Allergen quantitative risk assessment within food operations: Concepts towards development of practical guidance based on an ILSI Europe workshop

Benjamin C. Remington <sup>a</sup>, Joseph Baumert <sup>a</sup>, W. Marty Blom <sup>b</sup>, Luca Bucchini <sup>c</sup>, Neil Buck <sup>d</sup>, René Crevel<sup>e</sup>, Fleur De Mooij<sup>f</sup>, Simon Flanagan<sup>g</sup>, James Hindley<sup>h</sup>, Bushra Javed<sup>i</sup>, Despoina Angeliki Stavropoulou<sup>j,\*</sup>, Myrthe W. van den Dungen<sup>k</sup>, Marjan van Ravenhorst<sup>1</sup>, Si Wang m. Michael Walker n. Participants in the ILSI Europe Virtual Workshop of 29th October  $2020^{1}$ 



Release: June 2022

Guidance published (open access)


B

activity launch with the the Guidance Stakeholder community (Apr-Jul 2021)





### Different types of (Q)RA exist










## QRA isn't always necessary/appropriate or feasible










#### The Project Conduct: Participants






52 Stakeholders
Drafting by an ILSI Expert Group composed of 13 members



## Split into 3 Working Groups, across 2 distinct assessment categories

- Proactive assessments for food production under normal conditions (upstream and inhouse)
- Reactive assessments as part of an allergen incident response








#### WG 1: Supply Chain

- Up-steam communication with your supplier
- Establishing transparent flow of information








#### WG 2: Cross-contact - PAL

- cross-contact risk assessment for operations








#### **WG 3: Incidents**

- Unanticipated
- Errors outside of normal GMP or change management








WG 1:

**Supply Chain** 

**WG 2**:


**Cross-contamination - PAL** 

**WG 3: Incidents** 









#### Introduction

The place of QRA in allergen management

#### Communication Across the Supply Chain

- Global regulatory aspects
- Information requirements
- How to obtain the required information

#### Management of Operations

- QRA within allergen control programs
- Guide on QRA within site cross-contact
- Cleaning

#### Management of Incidents


Guidance on incident assessment

#### **Core Concepts**

- UAP Scenarios an characteristics
- Amount of UAP in food
- Guidance on Food intake
- Basic calculations


#### Annexes
















#### The Project Output: Core Concepts


#### Characteristics of UAP








## The Project Output: Core Concepts Example of how cross-contamination is characterized



|  | A   | morphous  | Particulate   |  |  |  |
|--|---|---|---|--|--|--|
| Homogeneous                              | structure, and is uniformly distributed within the sensitive product.                                   |   | UAP has a discrete structure, those discrete structures are uniformly distributed within the sensitive product at a particular density per unit volume. |  |  |  |
| Heterogeneous                            | UAP does not have a discrete structure, but is clumped in one or more regions of the sensitive product. |   | UAP has a discrete structure, those discrete structures are not uniformly distributed within the sensitive product.                                     |  |  |  |
| Form & Distribution: quality of evidence |   | <b>Description</b>  |   |  |  |  |
| High uncertainty                         |   | There is insufficient information to describe the form and/or distribution of UAP in the sensitive product.   |   |  |  |  |
| Med uncertainty                          |   | The form and/or distribution of UAP in the sensitive product can be inferred based on knowledge of materials and process, but has not been confirmed. |   |  |  |  |
|  |   | boon committed.   |   |  |  |  |

.


## The Project Output: Core Concepts The influence of UAP Characteristics on the calculation method





The Project Output: Core Concepts


**Estimating consumption** 







## The Project Output: Core Concepts Sampling & analysis








The Project Output: Core Concepts

Sampling & analysis




& Results

Results



## The Project Output: Core Concepts Sampling

| Supporting conditions to be considered | Regular frequency of<br>allergen presence<br>Low availability of material<br>samples<br>Homogeneous distribution of<br>allergens<br>Limited time & resource<br>available | Homogeneous distribution of allergens Limited time & resource available Sufficient or abundant material available to sample from Urgent and more resources made available | Sufficient or abundant material available to sample from  Urgent and more resources made available  |
|--|--|---|---|
| Level of                               | LOW  | MEDIUM  | HIGH  |
| concern                                | Routine verification of ingredients without claim  | Routine verification of ingredients without claim   | Quantification needed for risk assessment, claim validation or incident   |
| Number of<br>Samples<br>recommended    | A single or small number of samples  | Two up to six samples.  Particularly if allergen presence may be intermittent   | Allergen presence is regular and homogeneous: take at least six samples or two from every batch (risk based for claim validation).  |
|  |  | Sample size is also important   | Allergen presence is NOT regular and/or NOT homogeneous:<br>(i) consider the size of the batch and take " $\sqrt[3]{N}$ " [or $N^{(1/3)}$ ] samples, where N is the number of units available; or (ii) consider incremental sampling (see main text). |







#### The Project Output: Communication across the supply chain

#### Prioritization of ingredients

| Geographic complexity  | Ingredient / supplier complexity  | Supplier technical capability   |  |  |
|--|---|---|--|--|
| Low: Ingredients are being purchased from the same regulatory territory as the final product sales territory | Low: Homogeneous cross-contact risk 1. Low complexity environment 2. High complexity environment        | <b>High:</b> Company with dedicated people and verified systems for allergen management |  |  |
| High: Ingredients come from a regulatory territory other than the final product sales territory              | High: Heterogeneous cross-<br>contact risk 1. Low complexity environment 2. High complexity environment | Low: Company with few to no people or systems dedicated to allergen management          |  |  |

Given your use of the ingredient, how likely is it that a cross-contact will present health risk at market? Role for 'backwards' QRA.





#### The Project Output: Communication across the supply chain

#### Example supplier questionnaire

| 1. Allergen   Recipe/ product formula (added ingredients, additives, c from an allergenic source) |        |    |  | ocessing aids etc. derived |   |  | Cross contamination = possibly present (unintentional presence due to production on the same equipment, used utensils, personnel, airborne contact or by other means). |     |  |  |             |                    |
|---|--------|----|--|----------------------------|---|--|--|-----|--|--|-------------|--------------------|
|   | Used a |    | Type of ingredient<br>E.g. peanut oil, soy<br>lecithin, wheat starch,<br>celery seed | Com-<br>position           | Protein content<br>from allergenic<br>source (%) <sup>1</sup> |  | om on possible? could cause cross contar<br>lergen same E.g. peanut oil, soy lecith  |     | could cause cross contact.<br>E.g. peanut oil, soy lecithin, | Type of contamination Homogeneous: powder, liquid of paste. Inhomogeneous: particles. Provide detailed information of the contamination <sup>4</sup> |             |                    |
|   | YES    | ИО |  | %                          | %   |  | YES  | YES | NO   |  | Homogeneous | Particle           |
| Cereals containing gluten   |        |    |  |                            |   |  |  |     |  |  |             |                    |
| Wheat   |        |    | ingredient name  | % recipe                   | protein %   |  |  |     |  | yes->ingredient name   | ppm         | ☐ grams, protein % |
| Rye   |        |    | ingredient name  | % recipe                   | protein %   |  |  |     |  | yes->ingredient name   | □ ppm       | grams, protein %   |
| Barley  |        |    | ingredient name  | % recipe                   | protein %   |  |  |     |  | yes->ingredient name   | □ ppm       | ☐ grams, protein % |
| Oats  |        |    | ingredient name  | % recipe                   | protein %   |  |  |     |  | yes->ingredient name   | □ ppm       | ☐ grams, protein % |
|   |        |    |  |                            |   |  |  |     |  |  |             |                    |






#### The Project Output: Communication across the supply chain

Supplier questionnaires and level of risk can be integrated with the other tools in your supplier-management arsenal














#### The Project Output: Management of Operations

#### Step 2 Step 3 Step 4 Step1 Implement Hazard Chance of Validation of characterization & Hazard Identification Risk Management Occurrence Controls Controls Identify the chance that Update & implement Identify the characteristics Apply validation Map the process and identify sources x-contact may occur of x-contact procedures allergen management and points of plan, including labeling where appropriate. potential x-contact For x-contact scenarios, For points of x-contact Identify controls subject that have an 'unknown' identify appropriate to validation that controls. Including identify chance of occurrence. potentially are not controls that may not fully gather more adequate at preventing mitigate x-contact. information x-contact For x-contact points For x-contact scenarios Apply QRA if it is possible that have a 'low' where the available control chance of occurrence may not fully mitigate. stop. In the case of identify opportunities to 'high' go to Step 3 improve control. For a control that cannot Based on Step 3 and 4. fully mitigate x-contact proceed with scenario, consider if QRA knowledge on whether is possible (eg carry-over x-contact is fully calculation) mitigated or not. For control measures that require validation, proceed to Step 4.






## The Project Output: Management of Operations Process mapping






The Project Output: Management of Operations

Change over












#### Type of Incident
























Chance of occurrence of contamination (is it real) ?

| Chance of Occurrence | Description   | Recommended Action  |
|----------------------|---|---|
| High                 | It is more likely than not that UAP has occurred:  The factors that cause contamination are known, and there is acceptable uncertainty that those factors have happened.                            | Proceed with the assessment (next step Track & Trace).  |
| Medium               | It is possible that UAP has occurred, but also likely it has not:  The factors that may cause contamination are known, and there is significant uncertainty on whether those factors have happened. | Gather data to decrease uncertainty on whether the incident has occurred.  or  If due to level of concern or time constraints proceed with the assessment, when/ if data becomes available repeat assessment of chance of occurrence. |
| Low or unknown       | There is circumstantial evidence only that UAP has occurred: Whether the contamination occurs or not cannot be estimated with acceptable level of certainty.  | Gather data to decrease uncertainty before progressing with an assessment.  |





Data Capture: Product consumption per eating occasion, Consider sampling & analysis, Tier of refinement, Data & Uncertainty

#### Tier 2 Tier 3 Tier 4 Tier 1 First Data Data indication First indication of potential available on available on that your incident your supply consumer supply chain chain product affected





Data Capture: Product consumption per eating occasion,
Consider sampling & analysis, Tier of refinement, Data & Uncertainty

| Data & Uncertainty  |   |   |  |  |  |  |
|---|---|---|--|--|--|--|
| aracteristics   | Uncertainty   | Data & Notes  |  |  |  |  |
| ☐ Amorphous   | 1 ☐ High  |   |  |  |  |  |
| ☐ Particulate   | 2  Medium   |   |  |  |  |  |
| ☐ Unknown<br>(uncertainty is always 'high')   | 3 ☐ Acceptable  | Note: If 'unknown', assessment should be based on both amorphous and particulate, until refined information is available.   |  |  |  |  |
| ☐ Homogeneous   | 1 □ High  |   |  |  |  |  |
| ☐ Heterogeneous   | 2  Medium   |   |  |  |  |  |
| ☐ Unknown<br>(uncertainty is always 'high')   | 3 ☐ Acceptable  | Note: If 'unknown', assessment should be based on both hetero' and homogeneous, until refined information is available.   |  |  |  |  |
| ☐ Isolated  | 1 □ High  |   |  |  |  |  |
| ☐ Intermittent  | 2  Medium   |   |  |  |  |  |
| □ Regular   | 3 ☐ Acceptable  |   |  |  |  |  |
| ☐ unknown<br>(uncertainty is always 'high')   |   | Note: If 'unknown', assessment should assume contamination is 'regular'.  |  |  |  |  |
| 1 ☐ Estimate – not analytical   |   | Provide data:   |  |  |  |  |
| 2  Analytical, point data   |   |   |  |  |  |  |
| 3  Analytical, data range. Or understanding of quantity available in case of mis-labeling or wrong ingredient used. |   | Note: If 'unknown', assessment can only be<br>qualitative. More information is needed before QRA<br>can be performed.   |  |  |  |  |
|   | 4.7 🗆 Ulah  | Notes   |  |  |  |  |
| ertainty (Sum Of A-D)   |   | Notes   |  |  |  |  |
|   |   |   |  |  |  |  |
|   | □ Amorphous □ Particulate □ Unknown (uncertainty is always 'high') □ Homogeneous □ Heterogeneous □ Unknown (uncertainty is always 'high') □ Isolated □ Intermittent □ Regular □ unknown (uncertainty is always 'high') 1 □ Estimate – not analyti 2 □ Analytical, point data 3 □ Analytical, data range of quantity available in case | Amorphous 1 High  Particulate 2 Medium  Unknown (uncertainty is always 'high')  Homogeneous 1 High  Heterogeneous 2 Medium  Unknown (uncertainty is always 'high')  Isolated 1 High  Intermittent 2 Medium  Regular 3 Acceptable  unknown (uncertainty is always 'high')  Estimate – not analytical  Analytical, data range. Or understanding of quantity available in case of mis-labeling or wrong ingredient used. |  |  |  |  |







| Tier of    | Overall Data Uncertainty |                         |                         |  |  |  |  |
|------------|--------------------------|-------------------------|-------------------------|--|--|--|--|
| Refinement | High                     | Medium                  | Acceptable              |  |  |  |  |
| 1*         | Uncertainty too large,   | Uncertainty too large,  | Uncertainty too large,  |  |  |  |  |
|            | more data required       | more data required      | more data required      |  |  |  |  |
| 2*         | Uncertainty too large,   | Qualitative assessment  | Qualitative or          |  |  |  |  |
|            | more data required       | only                    | Quantitative assessment |  |  |  |  |
| 3          | Qualitative or           | Quantitative assessment | Quantitative assessment |  |  |  |  |
|            | Quantitative             |                         |                         |  |  |  |  |
|            | assessment               |                         |                         |  |  |  |  |
| 4          | Quantitative             | Quantitative assessment | Quantitative assessment |  |  |  |  |
|            | assessment               |                         |                         |  |  |  |  |

<sup>\*</sup>A 'reverse' QRA may be useful to understand the amount of UAP that would present concern, to enable evaluation of whether that amount is feasible given the UAP scenario.






Outcome: Risk & Uncertainty; Proposed risk mitigation; Regulatory considerations

| Key Output                        |                           | Evidence                      |            |             | ]                         |       |
|-----------------------------------|---------------------------|-------------------------------|------------|-------------|---------------------------|-------|
| Risk Assessment Outcome           | There is a risk to allerg | ic consumers                  |            |             |                           |       |
|                                   | Risk within agreed limi   | ts of acceptability           |            |             |                           |       |
|                                   | Not currently possible    | to determine                  |            |             |                           |       |
| Proposed risk mitigation (in case |                           |                               |            |             |                           |       |
| of risk to allergic consumers)    |                           |                               |            |             |                           |       |
| Need to contact external          | Eg authority, patient o   | rg ?                          |            |             |                           |       |
| agencies                          |                           |                               |            |             |                           |       |
| Method of assessment              | Qualitative               |                               | 🗆          |             |                           |       |
|                                   | Quantitative (QRA)        |                               | 🗆          |             |                           |       |
|                                   | Not currently possible    | to assess                     |            |             | ]                         |       |
| Regulatory implications           |                           | Quality of Evidence Framework |            |             |                           | score |
|                                   | Product Presenta          | Tier of refinement            |            | Tier 1 – th | neoretical                | 1     |
| Describe aspects of product       | For example, partial ri   |                               |            | Tier 2 – in | formed                    | 2     |
| presentation that may modify      | exacerbation due to u     |                               |            | Tier 3 – da | ata-driven                | 3     |
| the risk                          |                           |                               |            | Tier 4 – ve | erified                   | 4     |
|                                   |                           | Chance that contam            | ination is | High or kr  | nown to have happened     | 3     |
|                                   |                           | occurring                     |            | Medium      |                           | 2     |
|                                   |                           |                               |            | Low or un   | known                     | 1     |
|                                   |                           | Overall data uncerta          | inty       | High unce   |                           | 1     |
|                                   |                           |                               |            | 1           | uncertainty               | 2     |
|                                   |                           |                               |            | Acceptabl   | le uncertainty            | 3     |
| <u> </u>                          |                           | Quality of Evidence           |            | 9 – 10 : hi | gh quality evidence       |       |
| <i>M</i> 11 21                    |                           |                               |            | 6-8:me      | dium quality evidence     |       |
|                                   |                           |                               |            | 5 and belo  | ow : low quality evidence |       |







#### Introduction

The place of QRA in allergen management

#### Communication Across the Supply Chain

- Global regulatory aspects
- Information requirements
- How to obtain the required information

#### Management of Operations

- QRA within allergen control programs
- Guide on QRA within site cross-contact
- Cleaning

#### Management of Incidents

Guidance on incident assessment

#### **Core Concepts**

- UAP Scenarios an characteristics
- Amount of UAP in food
- Guidance on Food intake
- Basic calculations

#### Annexes



### **Key points**

Improving PAL requires implementation of allergen QRA

#### but ...

- > The benefit to consumers of allergen QRA will only come if there is consistent application
- > There is a growing expectation that allergen QRA will be applied but ...
- Application is only relevant in specific situations to support established practices
- Misapplication will mislead

#### Bonus:

QRA cannot be implemented without an improved understanding of cross-contamination within supply chains

#### So:

A wide stakeholder group has developed consensus guidance





### **Next steps**

- Launch webinar for the Guidance document
- > Release of training sessions
- Collection of further inputs, learnings and periodic update of the guidance





#### Summary

#### Yesterday

- ➤ Binary Approach
- judgement on whether allergen is potentially present or not
- lack of industry alignment
- ➤ Inaccurate information passed along supply chains
- Proliferation of Inaccurate Precautionary Labelling

#### **Today**

- Growing expectation of more accurate crosscontact understanding
- Application of allergen reference doses, and QRA

#### But ...

Lack of harmonization in when allergen QRA is appropriate and how to perform

#### **Tomorrow**

Consensus guidance on the application of allergen QRA







www.ilsi.eu www.foodprotection.org

## Thank you for your attention



